“rbc-capital-markets” Archives

in
Entry Author Date Location
Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO 10/01/19 New York
Enanta Steps Forward in NASH Race, With Unclear Prospects 09/26/19 Boston
FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb 09/11/19 San Francisco
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet 08/30/19 Boston
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal 08/26/19 New York
Four New Drugs Are Around the Corner. Here’s What You Need to Know. 08/15/19 National
Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug 08/05/19 New York
Duchenne Advocates Start Casimir, Aiming to Capture Missing Data 07/26/19 Boston
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
Gilead Ups Stake in Galapagos With $5B Deal to Jumpstart Its R&D 07/15/19 San Francisco
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Adieu to Adu: Biogen’s Big Alzheimer’s Bet Flops, Shares Routed 03/21/19 Boston
FDA Staff Hammers Karyopharm Cancer Drug on Safety, Efficacy Concerns 02/22/19 Boston
Amgen Migraine Decision Looms, Maybe the Next Drug Price Fight, Too 05/16/18 National
Sage Postpartum Depression Drug Heads to FDA Review 04/23/18 Boston
FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” 02/27/18 New York
After Paper Shakes Sector, Gene Therapy Leader Jim Wilson Talks Safety 01/30/18 National
Five Prime Shares Dive on Latest Hiccup For Cancer Immunotherapy Combos 11/07/17 San Francisco
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More 08/29/17 Boston
Analysts Expect Payer Pushback as PTC Sets $35K Price For Duchenne Drug 05/08/17 New York
Sanders, Cummings to PTC: Price Duchenne Steroid at Import Cost 03/22/17 New York
With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work 03/17/17 San Francisco
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits 01/30/17 San Francisco
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval 01/24/17 Boston
Biogen to Pay $1.25B to Settle Forward Pharma Patent Suit on MS Drug 01/17/17 Boston
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Amyloid Hypothesis Lives On—Solanezumab, Too, Despite “Siren Song” 12/09/16 Indiana
Page 1 of 3 next page »